FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613012061> ?p ?o ?g. }

• W2613012061 endingPage "715" @default.
• W2613012061 startingPage "707" @default.
• W2613012061 abstract "Background Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. Methods We calibrated a compartmental model to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resistance, assuming no fitness cost of resistance from 2000 to 2040 in India, the Philippines, Russia, and South Africa. Findings The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12·4% (95% prediction interval 9·4–16·2) in India, 8·9% (4·5–11·7) in the Philippines, 32·5% (27·0–35·8) in Russia, and 5·7% (3·0–7·6) in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% (95% prediction interval 5·1–12·9) in India, 9·0% (4·0–14·7) in the Philippines, 9·0% (4·8–14·2) in Russia, and 8·5% (2·5–14·7) in South Africa in 2040. Acquired drug resistance would cause less than 30% of incident MDR tuberculosis during 2000–40. Acquired drug resistance caused 80% of incident XDR tuberculosis in 2000, but this estimate would decrease to less than 50% by 2040. Interpretation MDR and XDR tuberculosis were forecast to increase in all four countries despite improvements in acquired drug resistance shown by the Green Light Committee-supported programmatic management of drug-resistant tuberculosis. Additional control efforts beyond improving acquired drug resistance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden of MDR tuberculosis. Funding US Agency for International Development and US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. We calibrated a compartmental model to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resistance, assuming no fitness cost of resistance from 2000 to 2040 in India, the Philippines, Russia, and South Africa. The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12·4% (95% prediction interval 9·4–16·2) in India, 8·9% (4·5–11·7) in the Philippines, 32·5% (27·0–35·8) in Russia, and 5·7% (3·0–7·6) in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% (95% prediction interval 5·1–12·9) in India, 9·0% (4·0–14·7) in the Philippines, 9·0% (4·8–14·2) in Russia, and 8·5% (2·5–14·7) in South Africa in 2040. Acquired drug resistance would cause less than 30% of incident MDR tuberculosis during 2000–40. Acquired drug resistance caused 80% of incident XDR tuberculosis in 2000, but this estimate would decrease to less than 50% by 2040. MDR and XDR tuberculosis were forecast to increase in all four countries despite improvements in acquired drug resistance shown by the Green Light Committee-supported programmatic management of drug-resistant tuberculosis. Additional control efforts beyond improving acquired drug resistance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden of MDR tuberculosis." @default.
• W2613012061 created "2017-05-19" @default.
• W2613012061 creator A5001647611 @default.
• W2613012061 creator A5001709140 @default.
• W2613012061 creator A5010689312 @default.
• W2613012061 creator A5011112265 @default.
• W2613012061 creator A5016400476 @default.
• W2613012061 creator A5023107984 @default.
• W2613012061 creator A5024915830 @default.
• W2613012061 creator A5025087234 @default.
• W2613012061 creator A5033688269 @default.
• W2613012061 creator A5039644862 @default.
• W2613012061 creator A5049671547 @default.
• W2613012061 creator A5053817241 @default.
• W2613012061 creator A5061994881 @default.
• W2613012061 creator A5063418676 @default.
• W2613012061 creator A5066370166 @default.
• W2613012061 creator A5068801614 @default.
• W2613012061 creator A5068833847 @default.
• W2613012061 creator A5071897207 @default.
• W2613012061 creator A5075880658 @default.
• W2613012061 creator A5081083991 @default.
• W2613012061 creator A5081279738 @default.
• W2613012061 creator A5081289785 @default.
• W2613012061 creator A5087777538 @default.
• W2613012061 date "2017-07-01" @default.
• W2613012061 modified "2023-10-02" @default.
• W2613012061 title "Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study" @default.
• W2613012061 cites W1973150143 @default.
• W2613012061 cites W1981511719 @default.
• W2613012061 cites W2020018978 @default.
• W2613012061 cites W2054364721 @default.
• W2613012061 cites W2066527389 @default.
• W2613012061 cites W2070033302 @default.
• W2613012061 cites W2089465091 @default.
• W2613012061 cites W2089836296 @default.
• W2613012061 cites W2090640084 @default.
• W2613012061 cites W2091969879 @default.
• W2613012061 cites W2111683742 @default.
• W2613012061 cites W2112147097 @default.
• W2613012061 cites W2115422335 @default.
• W2613012061 cites W2115874732 @default.
• W2613012061 cites W2121472688 @default.
• W2613012061 cites W2127258416 @default.
• W2613012061 cites W2138041013 @default.
• W2613012061 cites W2140193283 @default.
• W2613012061 cites W2145931216 @default.
• W2613012061 cites W2150047352 @default.
• W2613012061 cites W2159470927 @default.
• W2613012061 cites W2164225859 @default.
• W2613012061 cites W2176621021 @default.
• W2613012061 cites W2319922541 @default.
• W2613012061 doi "https://doi.org/10.1016/s1473-3099(17)30247-5" @default.
• W2613012061 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5599934" @default.
• W2613012061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28499828" @default.
• W2613012061 hasPublicationYear "2017" @default.
• W2613012061 type Work @default.
• W2613012061 sameAs 2613012061 @default.
• W2613012061 citedByCount "103" @default.
• W2613012061 countsByYear W26130120612017 @default.
• W2613012061 countsByYear W26130120612018 @default.
• W2613012061 countsByYear W26130120612019 @default.
• W2613012061 countsByYear W26130120612020 @default.
• W2613012061 countsByYear W26130120612021 @default.
• W2613012061 countsByYear W26130120612022 @default.
• W2613012061 countsByYear W26130120612023 @default.
• W2613012061 crossrefType "journal-article" @default.
• W2613012061 hasAuthorship W2613012061A5001647611 @default.
• W2613012061 hasAuthorship W2613012061A5001709140 @default.
• W2613012061 hasAuthorship W2613012061A5010689312 @default.
• W2613012061 hasAuthorship W2613012061A5011112265 @default.
• W2613012061 hasAuthorship W2613012061A5016400476 @default.
• W2613012061 hasAuthorship W2613012061A5023107984 @default.
• W2613012061 hasAuthorship W2613012061A5024915830 @default.
• W2613012061 hasAuthorship W2613012061A5025087234 @default.
• W2613012061 hasAuthorship W2613012061A5033688269 @default.
• W2613012061 hasAuthorship W2613012061A5039644862 @default.
• W2613012061 hasAuthorship W2613012061A5049671547 @default.
• W2613012061 hasAuthorship W2613012061A5053817241 @default.
• W2613012061 hasAuthorship W2613012061A5061994881 @default.
• W2613012061 hasAuthorship W2613012061A5063418676 @default.
• W2613012061 hasAuthorship W2613012061A5066370166 @default.
• W2613012061 hasAuthorship W2613012061A5068801614 @default.
• W2613012061 hasAuthorship W2613012061A5068833847 @default.
• W2613012061 hasAuthorship W2613012061A5071897207 @default.
• W2613012061 hasAuthorship W2613012061A5075880658 @default.
• W2613012061 hasAuthorship W2613012061A5081083991 @default.
• W2613012061 hasAuthorship W2613012061A5081279738 @default.
• W2613012061 hasAuthorship W2613012061A5081289785 @default.
• W2613012061 hasAuthorship W2613012061A5087777538 @default.
• W2613012061 hasBestOaLocation W26130120611 @default.
• W2613012061 hasConcept C114851261 @default.
• W2613012061 hasConcept C133936738 @default.
• W2613012061 hasConcept C142724271 @default.
• W2613012061 hasConcept C2777107064 @default.
• W2613012061 hasConcept C2777975735 @default.
• W2613012061 hasConcept C2781069245 @default.
• W2613012061 hasConcept C71924100 @default.

• next